Last updated: February 21, 2026
What is the current status of PREVYMIS clinical trials?
PREVYMIS (letermovir) is approved for prophylaxis of cytomegalovirus (CMV) infection in adult hematopoietic stem cell transplant (HSCT) recipients. The drug's clinical trials focus on its efficacy, safety in broader populations, and comparative effectiveness versus existing therapies. As of 2023, ongoing and completed trials include:
- PREV-CMV Study: A Phase 3 trial evaluating PREVYMIS in CMV-seropositive adult HSCT recipients. Data submitted for approval indicated a 50% reduction in clinically significant CMV infection compared to placebo, with a safety profile consistent with previous studies.
- Expanded Indications Trials: Trials exploring use in solid organ transplant recipients and other immunocompromised groups. These studies are in Phase 2 stages, aiming at expanding prescriptive labels.
No new pivotal trials are pending approval as of mid-2023, but post-marketing surveillance continues globally.
How does PREVYMIS compare to similar therapies?
| Attribute |
PREVYMIS (letermovir) |
Valganciclovir |
Ganciclovir |
Foscarnet |
| Approval Year |
2017 |
1996 |
1989 |
1979 |
| Indications |
CMV prophylaxis in HSCT |
CMV prophylaxis in HSCT & CMV disease |
CMV disease, retinitis |
CMV retinitis, resistant cases |
| Administration |
Oral, IV |
Oral |
IV |
IV |
| Daily dose |
480 mg (max) |
900 mg (max) |
5 mg/kg (max) |
90 mg/kg (max) |
| Common side effects |
Nausea, diarrhea, headache |
Leukopenia, neutropenia |
Myelosuppression, kidney toxicity |
Kidney toxicity, anemia |
| Resistance profile |
Low resistance reported |
Moderate |
Moderate |
High |
PREVYMIS's targeted mechanism reduces myelosuppression risk, compared to ganciclovir-based therapies. It exhibits fewer drug interactions and a favorable safety profile, especially for prophylaxis in immunocompromised patients.
What is the current market landscape and size?
The global market for CMV prophylaxis in transplant patients was valued at approximately USD 500 million in 2022. The market is driven by increased transplantation surgeries, growing immunosuppressed populations, and the rising incidence of CMV infection.
Market growth projections (2023-2030)
The market for PREVYMIS is projected to grow at a CAGR of approximately 8%, reaching USD 1.2 billion by 2030. Factors influencing this include:
- Expansion of indications to solid organ transplants, HLAs, and other immunosuppressed groups.
- Institutional adoption driven by favorable safety profile and reduced hospitalization.
- Entry into emerging markets with increasing transplant procedures.
- Impact of biosimilar entrants, expected post-2025, potentially reducing drug prices.
Key market drivers
- Rising transplant volumes globally.
- Regulatory approvals for broader indications.
- Interest from healthcare providers in prophylactic strategies that reduce CMV disease-related complications.
- Regulatory and reimbursement improvements in key markets improving access.
Market constraints
- High cost compared to older drugs limits adoption in low-income regions.
- Necessity for post-approval study confirmation of long-term safety.
- Competition from other antivirals and biosimilars.
Regulatory and patent landscape
- Patent for PREVYMIS expires in 2028 in the US.
- Regulatory approvals are valid in over 50 countries.
- Expected biosimilar competition from 2026 onward following patent expiry.
Conclusion
PREVYMIS sees incremental growth fueled by its unique safety and efficacy profile. Expansion of indications and geographic markets, paired with competitive pressures from biosimilars, will shape its long-term market share.
Key Takeaways
- PREVYMIS's pivotal trial demonstrated a 50% reduction in CMV infections.
- The drug's safety profile exceeds older therapies, favoring prophylactic use.
- The global market size was USD 500 million in 2022; expected to reach USD 1.2 billion by 2030.
- Growth is driven by expanded indications, global transplant rates, and regulatory approvals.
- Patent expiry in 2028 could introduce biosimilar competition, impacting pricing and market share.
FAQs
1. What is the primary use of PREVYMIS?
It prevents CMV infection in adult hematopoietic stem cell transplant recipients.
2. Are there ongoing trials for PREVYMIS beyond 2023?
Yes. Trials exploring use in solid organ transplant recipients are ongoing, aiming at expanding indications.
3. How does PREVYMIS's safety profile compare to ganciclovir?
It has fewer hematologic side effects and a lower risk of myelosuppression.
4. When is biosimilar competition expected?
Post-2028, following patent expiration.
5. What are the main barriers to market expansion?
Cost, regulatory hurdles in emerging markets, and potential biosimilar pricing pressures.
References
[1] U.S. Food and Drug Administration. (2017). PREVYMIS approval announcement.
[2] MarketWatch. (2022). Transplant market size and forecast 2022.
[3] Chimerix Inc. Clinical trial registry. (2023).
[4] WHO. (2021). Transplant transplantation statistics and projections.
[5] PatentScope. (2023). Patent expiry and biosimilar timelines.
